Which has stronger valuation & earnings, VCEL or PTGX?

Vericel has higher revenue and earnings than Protagonist Therapeutics. Vericel is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 8.30 $16.52M $0.47 95.21 Protagonist Therapeutics $46.02M 207.33 -$130.15M $1.03 144.04

Does the media favor VCEL or PTGX?

In the previous week, Protagonist Therapeutics had 11 more articles in the media than Vericel. MarketBeat recorded 24 mentions for Protagonist Therapeutics and 13 mentions for Vericel. Vericel's average media sentiment score of 0.72 beat Protagonist Therapeutics' score of 0.53 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, SYRE or VCEL?

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyre Therapeutics $890K 10,378.50 -$155.20M -$1.95 N/A Vericel $276.26M 8.30 $16.52M $0.47 95.21

Does the media refer more to SYRE or VCEL?

In the previous week, Spyre Therapeutics had 10 more articles in the media than Vericel. MarketBeat recorded 23 mentions for Spyre Therapeutics and 13 mentions for Vericel. Vericel's average media sentiment score of 0.72 beat Spyre Therapeutics' score of 0.62 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 8 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VCEL or IONS?

In the previous week, Ionis Pharmaceuticals had 8 more articles in the media than Vericel. MarketBeat recorded 21 mentions for Ionis Pharmaceuticals and 13 mentions for Vericel. Vericel's average media sentiment score of 0.72 beat Ionis Pharmaceuticals' score of 0.19 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to PRAX or VCEL?

In the previous week, Praxis Precision Medicines had 10 more articles in the media than Vericel. MarketBeat recorded 23 mentions for Praxis Precision Medicines and 13 mentions for Vericel. Vericel's average media sentiment score of 0.72 beat Praxis Precision Medicines' score of 0.59 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 7 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Vericel 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, VCEL or KYMR?

Vericel has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 8.30 $16.52M $0.47 95.21 Kymera Therapeutics $39.21M 227.81 -$311.35M -$3.24 N/A

Does the media refer more to VCEL or KYMR?

In the previous week, Kymera Therapeutics had 16 more articles in the media than Vericel. MarketBeat recorded 29 mentions for Kymera Therapeutics and 13 mentions for Vericel. Vericel's average media sentiment score of 0.72 beat Kymera Therapeutics' score of -0.19 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral

Vericel (VCEL) Competitors

$44.64 -0.45 (-0.99%)

As of 12:01 PM Eastern

Compare

VCEL vs. PTGX, SYRE, IONS, PRAX, and KYMR

Should you buy Vericel stock or one of its competitors? MarketBeat compares Vericel with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vericel include Protagonist Therapeutics (PTGX), Spyre Therapeutics (SYRE), Ionis Pharmaceuticals (IONS), Praxis Precision Medicines (PRAX), and Kymera Therapeutics (KYMR). These companies are all part of the "biotechnology" industry.

How does Vericel compare to Protagonist Therapeutics?

Vericel (NASDAQ:VCEL) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

In the previous week, Protagonist Therapeutics had 11 more articles in the media than Vericel. MarketBeat recorded 24 mentions for Protagonist Therapeutics and 13 mentions for Vericel. Vericel's average media sentiment score of 0.72 beat Protagonist Therapeutics' score of 0.53 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has a net margin of 29.40% compared to Vericel's net margin of 7.91%. Protagonist Therapeutics' return on equity of 12.03% beat Vericel's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Protagonist Therapeutics	29.40%	12.03%	11.23%

Vericel has higher revenue and earnings than Protagonist Therapeutics. Vericel is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	8.30	$16.52M	$0.47	95.21
Protagonist Therapeutics	$46.02M	207.33	-$130.15M	$1.03	144.04

98.6% of Protagonist Therapeutics shares are held by institutional investors. 7.6% of Vericel shares are held by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Vericel currently has a consensus price target of $58.40, indicating a potential upside of 30.50%. Protagonist Therapeutics has a consensus price target of $132.14, indicating a potential downside of 10.93%. Given Vericel's higher probable upside, equities analysts plainly believe Vericel is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Protagonist Therapeutics	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.00

Vericel has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Vericel on 12 of the 17 factors compared between the two stocks.

How does Vericel compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Vericel (NASDAQ:VCEL) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Vericel has a net margin of 7.91% compared to Spyre Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.91% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Vericel	7.91%	6.91%	5.02%

Spyre Therapeutics currently has a consensus target price of $110.15, suggesting a potential upside of 4.87%. Vericel has a consensus target price of $58.40, suggesting a potential upside of 30.50%. Given Vericel's higher possible upside, analysts plainly believe Vericel is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Spyre Therapeutics had 10 more articles in the media than Vericel. MarketBeat recorded 23 mentions for Spyre Therapeutics and 13 mentions for Vericel. Vericel's average media sentiment score of 0.72 beat Spyre Therapeutics' score of 0.62 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	8 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	10,378.50	-$155.20M	-$1.95	N/A
Vericel	$276.26M	8.30	$16.52M	$0.47	95.21

Spyre Therapeutics has a beta of 3.03, suggesting that its stock price is 203% more volatile than the broader market. Comparatively, Vericel has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 7.6% of Vericel shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Vericel beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Vericel compare to Ionis Pharmaceuticals?

Vericel (NASDAQ:VCEL) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Vericel presently has a consensus price target of $58.40, indicating a potential upside of 30.50%. Ionis Pharmaceuticals has a consensus price target of $94.65, indicating a potential upside of 64.71%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.77

Vericel has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 7.6% of Vericel shares are held by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Vericel has a net margin of 7.91% compared to Ionis Pharmaceuticals' net margin of -64.76%. Vericel's return on equity of 6.91% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

In the previous week, Ionis Pharmaceuticals had 8 more articles in the media than Vericel. MarketBeat recorded 21 mentions for Ionis Pharmaceuticals and 13 mentions for Vericel. Vericel's average media sentiment score of 0.72 beat Ionis Pharmaceuticals' score of 0.19 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Vericel has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	8.30	$16.52M	$0.47	95.21
Ionis Pharmaceuticals	$874.09M	10.93	-$381.39M	-$3.46	N/A

Summary

Vericel beats Ionis Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Vericel compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Vericel (NASDAQ:VCEL) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Praxis Precision Medicines presently has a consensus price target of $573.05, indicating a potential upside of 59.60%. Vericel has a consensus price target of $58.40, indicating a potential upside of 30.50%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, research analysts clearly believe Praxis Precision Medicines is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Praxis Precision Medicines has a beta of 2.78, indicating that its share price is 178% more volatile than the broader market. Comparatively, Vericel has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Vericel has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,172.48	-$303.27M	-$12.93	N/A
Vericel	$276.26M	8.30	$16.52M	$0.47	95.21

67.8% of Praxis Precision Medicines shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 7.6% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Praxis Precision Medicines had 10 more articles in the media than Vericel. MarketBeat recorded 23 mentions for Praxis Precision Medicines and 13 mentions for Vericel. Vericel's average media sentiment score of 0.72 beat Praxis Precision Medicines' score of 0.59 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Vericel	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel has a net margin of 7.91% compared to Praxis Precision Medicines' net margin of 0.00%. Vericel's return on equity of 6.91% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Vericel	7.91%	6.91%	5.02%

Summary

Vericel beats Praxis Precision Medicines on 9 of the 17 factors compared between the two stocks.

How does Vericel compare to Kymera Therapeutics?

Vericel (NASDAQ:VCEL) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

In the previous week, Kymera Therapeutics had 16 more articles in the media than Vericel. MarketBeat recorded 29 mentions for Kymera Therapeutics and 13 mentions for Vericel. Vericel's average media sentiment score of 0.72 beat Kymera Therapeutics' score of -0.19 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Vericel has a net margin of 7.91% compared to Kymera Therapeutics' net margin of -285.33%. Vericel's return on equity of 6.91% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

Vericel currently has a consensus target price of $58.40, indicating a potential upside of 30.50%. Kymera Therapeutics has a consensus target price of $125.65, indicating a potential upside of 16.97%. Given Vericel's higher possible upside, research analysts plainly believe Vericel is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Vericel has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market.

Vericel has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	8.30	$16.52M	$0.47	95.21
Kymera Therapeutics	$39.21M	227.81	-$311.35M	-$3.24	N/A

Summary

Vericel beats Kymera Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Vericel News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCEL vs. The Competition

Export

Metric	Vericel	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.28B	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	94.82	9.06	269.91	24.87
Price / Sales	8.30	1,278.42	654.69	108.21
Price / Cash	81.17	44.95	28.89	37.44
Price / Book	6.38	17.97	11.40	6.45
Net Income	$16.52M	-$13.25M	$3.45B	$347.50M
7 Day Performance	-2.82%	5.58%	3.66%	3.77%
1 Month Performance	-4.79%	-1.60%	-0.49%	-0.40%
1 Year Performance	23.48%	61.32%	77.51%	23.55%

Vericel Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCEL Vericel	4.2957 of 5 stars	$44.75 -0.8%	$58.40 +30.5%	+24.4%	$2.28B	$276.26M	94.82	300
PTGX Protagonist Therapeutics	1.4777 of 5 stars	$132.28 -3.2%	$123.00 -7.0%	+185.6%	$8.79B	$46.02M	N/A	120	Earnings Report Analyst Downgrade Analyst Revision Gap Up
SYRE Spyre Therapeutics	2.2025 of 5 stars	$94.93 -3.5%	$101.42 +6.8%	+592.0%	$8.65B	$890K	N/A	73	Earnings Report Analyst Upgrade
IONS Ionis Pharmaceuticals	3.7419 of 5 stars	$54.49 +5.3%	$94.65 +73.7%	+35.8%	$8.60B	$874.09M	N/A	1,402
PRAX Praxis Precision Medicines	3.8367 of 5 stars	$305.51 -0.8%	$563.50 +84.4%	+685.3%	$8.58B	$8.55M	N/A	110	Positive News Earnings Report Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCEL) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vericel (VCEL) Competitors

VCEL vs. PTGX, SYRE, IONS, PRAX, and KYMR

How does Vericel compare to Protagonist Therapeutics?

Summary

How does Vericel compare to Spyre Therapeutics?

Summary

How does Vericel compare to Ionis Pharmaceuticals?

Summary

How does Vericel compare to Praxis Precision Medicines?

Summary

How does Vericel compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vericel (VCEL) Competitors

VCEL vs. PTGX, SYRE, IONS, PRAX, and KYMR

How does Vericel compare to Protagonist Therapeutics?

Does the media favor VCEL or PTGX?

Is VCEL or PTGX more profitable?

Which has stronger valuation & earnings, VCEL or PTGX?

Do insiders & institutionals believe in VCEL or PTGX?

Do analysts rate VCEL or PTGX?

Which has more risk & volatility, VCEL or PTGX?

Summary

How does Vericel compare to Spyre Therapeutics?

Is SYRE or VCEL more profitable?

Do analysts recommend SYRE or VCEL?

Does the media refer more to SYRE or VCEL?

Which has preferable earnings and valuation, SYRE or VCEL?

Which has more volatility & risk, SYRE or VCEL?

Do insiders and institutionals hold more shares of SYRE or VCEL?

Summary

How does Vericel compare to Ionis Pharmaceuticals?

Do analysts rate VCEL or IONS?

Which has more volatility and risk, VCEL or IONS?

Do institutionals & insiders have more ownership in VCEL or IONS?

Is VCEL or IONS more profitable?

Does the media favor VCEL or IONS?

Which has stronger valuation and earnings, VCEL or IONS?

Summary

How does Vericel compare to Praxis Precision Medicines?

Do analysts rate PRAX or VCEL?

Which has more risk and volatility, PRAX or VCEL?

Which has better valuation and earnings, PRAX or VCEL?

Do institutionals and insiders have more ownership in PRAX or VCEL?

Does the media refer more to PRAX or VCEL?

Is PRAX or VCEL more profitable?

Summary

How does Vericel compare to Kymera Therapeutics?

Does the media refer more to VCEL or KYMR?

Is VCEL or KYMR more profitable?

Do analysts rate VCEL or KYMR?

Which has more volatility and risk, VCEL or KYMR?

Which has higher earnings & valuation, VCEL or KYMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools